Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis.

Literature DB >> 16187185

Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis.

Yoshihiro Numata¹, Susuma Tazuma, Yoshitaka Ueno, Tomoji Nishioka, Hideyuki Hyogo, Kazuaki Chayama.

Abstract

Primary sclerosing cholangitis is often complicated by ulcerative colitis. Recently, we reported on Th1-dominant cholangitis associated with experimental colitis, and natural killer T (NKT) cells might play an important role in this model. The aim of this study was to clarify the immunopathogenic role of NKT cells in this model using alpha-galactosylceramide. CD-1 mice were administered 2.0% dextran sulfate sodium for 29 days and injection of alpha-galactosylceramide was performed every 5 days, then inflammation was assessed. Mononuclear cells from the liver were analyzed with respect to cytokine production and the surface marker. alpha-Galactosylceramide improved survival rate, weight gain, and inflammation score. Also, interferon-gamma release from MNC, CD4/CD8 ratio, NKT cell population, and NK cell population were decreased by this treatment. These findings indicate that repeated stimulation of NKT cells modifies the Th1/Th2 balance to reduce Th1 dominance, and this may be a mechanism by which alpha-galactosylceramide has a therapeutic effect.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 16187185 DOI： 10.1007/s10620-005-2949-2

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

30 in total

1. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

Authors: N Singh; S Hong; D C Scherer; I Serizawa; N Burdin; M Kronenberg; Y Koezuka; L Van Kaer
Journal: J Immunol Date: 1999-09-01 Impact factor: 5.422

Review 2. Management of primary sclerosing cholangitis.

Authors: Young-Mee Lee; Marshall M Kaplan
Journal: Am J Gastroenterol Date: 2002-03 Impact factor: 10.864

3. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.

Authors: R Nakagawa; I Nagafune; Y Tazunoki; H Ehara; H Tomura; R Iijima; K Motoki; M Kamishohara; S Seki
Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422

4. NK1.1+ CD4+ T cells lose NK1.1 expression upon in vitro activation.

Authors: H Chen; H Huang; W E Paul
Journal: J Immunol Date: 1997-06-01 Impact factor: 5.422

5. Biliary tract disease in rats with experimental small bowel bacterial overgrowth.

Authors: S N Lichtman; J Keku; R L Clark; J H Schwab; R B Sartor
Journal: Hepatology Date: 1991-04 Impact factor: 17.425

6. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans.

Authors: K Kawakami; Y Kinjo; S Yara; Y Koguchi; K Uezu; T Nakayama; M Taniguchi; A Saito
Journal: Infect Immun Date: 2001-01 Impact factor: 3.441

7. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.

Authors: Y Osman; T Kawamura; T Naito; K Takeda; L Van Kaer; K Okumura; T Abo
Journal: Eur J Immunol Date: 2000-07 Impact factor: 5.532

8. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.

Authors: Mark J Smyth; Nadine Y Crowe; Daniel G Pellicci; Konstantinos Kyparissoudis; Janice M Kelly; Kazuyoshi Takeda; Hideo Yagita; Dale I Godfrey
Journal: Blood Date: 2002-02-15 Impact factor: 22.113

9. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.

Authors: Kiran Bambha; W Ray Kim; Jayant Talwalkar; Heidi Torgerson; Joanne T Benson; Terry M Therneau; Edward V Loftus; Barbara P Yawn; E Rolland Dickson; L Joseph Melton
Journal: Gastroenterology Date: 2003-11 Impact factor: 22.682

Review 10. Etiology and pathogenesis in primary sclerosing cholangitis.

Authors: K M Boberg; K E Lundin; E Schrumpf
Journal: Scand J Gastroenterol Suppl Date: 1994

9 in total

1. Pulverized konjac glucomannan ameliorates oxazolone-induced colitis in mice.

Authors: Toshiko Onitake; Yoshitaka Ueno; Shinji Tanaka; Shintaro Sagami; Ryohei Hayashi; Kenta Nagai; Michihiro Hide; Kazuaki Chayama
Journal: Eur J Nutr Date: 2014-09-25 Impact factor: 5.614

Review 2. Old and New Lymphocyte Players in Inflammatory Bowel Disease.

Authors: Paolo Giuffrida; Gino Roberto Corazza; Antonio Di Sabatino
Journal: Dig Dis Sci Date: 2017-12-23 Impact factor: 3.199

3. Association between chronic liver and colon inflammation during the development of murine syngeneic graft-versus-host disease.

Authors: J Anthony Brandon; Jacqueline Perez; C Darrell Jennings; Donald A Cohen; V J Sindhava; S Bondada; Alan M Kaplan; J Scott Bryson
Journal: Am J Physiol Gastrointest Liver Physiol Date: 2010-07-15 Impact factor: 4.052

Review 4. Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.

Authors: Madi El Haj; Ami Ben Ya'acov; Gadi Lalazar; Yaron Ilan
Journal: World J Gastroenterol Date: 2007-11-28 Impact factor: 5.742

Review 5. Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.

Authors: Philomena Arrenberg; Ramesh Halder; Vipin Kumar
Journal: J Cell Physiol Date: 2009-02 Impact factor: 6.384